Kezar Life Sciences (KZR) Misses Q3 EPS by 153c Nov 13, 2025 06:24AM
Kezar Life Sciences presents trial data at medical conferences Nov 7, 2025 07:03AM
William Blair Downgrades Kezer Life Sciences (KZR) to Market Perform Oct 17, 2025 04:47AM
Jefferies Downgrades Kezer Life Sciences (KZR) to Hold Oct 17, 2025 12:52AM
Kezar Life Sciences (KZR) Halted, News Pending Oct 16, 2025 04:01PM


Aug 13, 2025 06:19PM Kezar Life Sciences (KZR) Misses Q2 EPS by 187c
May 13, 2025 06:06PM Kezar Life Sciences (KZR) Misses Q1 EPS by 227c
Mar 25, 2025 07:30AM Kezar Life Sciences (KZR) Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of AIH and Reports Fourth Quarter and Year End 2024 Financial Res
Feb 28, 2025 07:26AM William Blair Upgrades Kezer Life Sciences (KZR) to Outperform
Dec 2, 2024 06:45AM H.C. Wainwright Reiterates Neutral Rating on Kezer Life Sciences (KZR)
Nov 13, 2024 06:25AM Kezar Life Sciences, Inc. (KZR) Misses Q3 EPS by 246c
Oct 28, 2024 08:30AM Kezar Life Sciences (KZR) Announces 1:10 Reverse Share Split
Oct 18, 2024 06:47AM H.C. Wainwright Reiterates Neutral Rating on Kezer Life Sciences (KZR)
Oct 17, 2024 08:35AM Kezar Life Sciences (KZR) Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Oct 17, 2024 08:30AM Kezar Life Sciences (KZR) Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib
Oct 14, 2024 07:23AM H.C. Wainwright Reiterates Neutral Rating on Kezer Life Sciences (KZR)
Oct 10, 2024 08:32AM Kezar Life Sciences (KZR) Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
Oct 8, 2024 04:41PM After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more
Oct 8, 2024 04:27PM Kezar Life Sciences (KZR) Shareholder Kevin Tang Offers to Acquire 100% of Company for $1.10 Per Share Plus CVR
Oct 4, 2024 05:00PM Kezar Life Sciences (KZR) Announces Clinical Hold of Zetomipzomib IND
Oct 1, 2024 07:49AM TD Cowen Reiterates Buy Rating on Kezer Life Sciences (KZR)
Sep 30, 2024 11:33AM Jones Trading Reiterates Hold Rating on Kezer Life Sciences (KZR)
Sep 30, 2024 08:30AM Kezar Life Sciences (KZR) Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib
Aug 14, 2024 02:16PM TD Cowen Reiterates Buy Rating on Kezer Life Sciences (KZR)
Aug 13, 2024 04:18PM Kezar Life Sciences, Inc. (KZR) Reports Q2 Loss of $0.30/sh